AbbVie (ABBV) Tops Q2 EPS by 3c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
William Blair Remains Bullish on AbbVie (ABBV) Following 2Q Beat
July 30, 2018 8:45 AM EDTWilliam Blair reiterated an Outperform rating and $127.00 price target on Abbvie (NYSE: ABBV) following the company's 2Q earnings report. Revenues for the quarter were $8.3 billion, beating consensus of $8.2 billion. Non-GAAP EPS were $2.00, above consensus of $1.97.
Management issued updated guidance for 2018 non-GAAP EPS of $7.76 to $7.86... More
Abbvie (ABBV) PT Lowered to $110 at Cowen
July 27, 2018 11:57 AM EDTCowen lowered its price target on Abbvie (NYSE: ABBV) to $110.00 (from $130.00) while maintaining an Outperform rating following beat and raise.
The firm is lowering the target based on a reduced target PE of 14x 2018 EPS (prior 17x) given lingering uncertainties (legal, pricing,... More
